Breast cancer is the second most common cause of death among women. With rising cases of breast cancer recorded worldwide, the need for developing an effective therapy has become a priority for many pharmaceutical and healthcare firms.....

Leber Hereditary Optic Neuropathy (LHON) is a hereditary form of vision loss that usually begins at teenage or in the early twenties. With few rare cases likely to occur in late adulthood or early childhood, various biotech firms are f....

With novel clinical trials, organizations across the world are developing new therapies and next-generation treatment for targeting fatal diseases such as cancer. The result of such clinical trials can aid the improvement in existing treatm....

Aesthetic medicine is increasingly being used for the treatment of physical impairments such as skin discoloration, excessive fat, scars, skin laxity, wrinkles, cellulite, and liver spots. Customer are seen demanding for resurfacing and non....

There is a substantial rise in the number of people affected with pulmonary diseases like asthma. Various pharmaceutical companies in the world are combining their capabilities to find treatments for serious pulmonary diseases to address th....

As cases of neurodegenerative diseases like Alzheimer’s and Parkinson’s are on a rise, biopharmaceutical firms are actively engaging in developing new clinical drugs. Companies are also gaining increased funding from partners to....

With heart related issues and number of people diagnosed with heart failure increasing substantially, the need to find a solution to this problem is growing considerably. Advanced technology, equipment and pharmaceutical companies are conti....

Customer Experience (CX) is vital for companies to understand the mindset of their clients. Industries are actively investing in customer experience solutions to stay ahead in competition. Companies are also partnering with other market pla....

Patients having Relapsed-refractory multiple myeloma (RRMM) along with extramedullary disease (EMD) will be treated by Oncopeptides AB. In the company’s HORIZON trial, a cumulative response rate of 23% was attained with dexamethaso....

As part of the 5-year agreement, Vertex will also be collecting real world data on these medicines. Vertex Pharmaceuticals Incorporated has reportedly announced that Scotland based patients suffering from cystic fibrosis will now be eligib....